BACKGROUND: To evaluate the peripheral neuropathic changes induced by combination chemotherapy including paclitaxel (taxol), gemcitabine and cisplatin (TGC regimen). PATIENTS AND METHODS: Eighteen patients with primary or recurrent ovarian cancer were treated with paclitaxel 150 or 110 mg/m2, respectively, together with gemcitabine 800 mg/m2 and cisplatin 75 mg/m2, 3 weekly for 6 cycles. Neurologic evaluation and quantitative assessment by vibration perception threshold (VPT) and grip strength took place before therapy, after 3 and 6 cycles of chemotherapy, and thereafter when possible. RESULTS: Both neuropathic symptoms and signs developed in all patients (100%), becoming most prominent 3 months after the last course of chemotherapy. Grade 3 peripheral neuropathy developed in one patient during chemotherapy, and in 3 additional patients after cessation of therapy. No significant differences were observed between chemo-naive patients and pretreated patients. CONCLUSION: This TGC combination is well tolerated in terms of peripheral neuropathy during therapy, although the off-therapy worsening caused by cisplatin remains a problem.
BACKGROUND: To evaluate the peripheral neuropathic changes induced by combination chemotherapy including paclitaxel (taxol), gemcitabine and cisplatin (TGC regimen). PATIENTS AND METHODS: Eighteen patients with primary or recurrent ovarian cancer were treated with paclitaxel 150 or 110 mg/m2, respectively, together with gemcitabine 800 mg/m2 and cisplatin 75 mg/m2, 3 weekly for 6 cycles. Neurologic evaluation and quantitative assessment by vibration perception threshold (VPT) and grip strength took place before therapy, after 3 and 6 cycles of chemotherapy, and thereafter when possible. RESULTS: Both neuropathic symptoms and signs developed in all patients (100%), becoming most prominent 3 months after the last course of chemotherapy. Grade 3 peripheral neuropathy developed in one patient during chemotherapy, and in 3 additional patients after cessation of therapy. No significant differences were observed between chemo-naive patients and pretreated patients. CONCLUSION: This TGC combination is well tolerated in terms of peripheral neuropathy during therapy, although the off-therapy worsening caused by cisplatin remains a problem.
Authors: G J Peters; V W Ruiz van Haperen; A M Bergman; G Veerman; E Smitskamp-Wilms; C J van Moorsel; C M Kuiper; B J Braakhuis Journal: Semin Oncol Date: 1996-10 Impact factor: 4.929
Authors: G Frasci; N Panza; P Comella; G P Nicolella; M Natale; L Manzione; D Bilancia; R Cioffi; L Maiorino; G De Cataldis; M Belli; E Micillo; V Mascia; B Massidda; V Lorusso; M De Lena; F Carpagnano; A Contu; G Pusceddu; G Comella Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: E K Rowinsky; V Chaudhry; A A Forastiere; S E Sartorius; D S Ettinger; L B Grochow; B G Lubejko; D R Cornblath; R C Donehower Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544